177 related articles for article (PubMed ID: 20664929)
1. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2010 Sep; 37(3):605-14. PubMed ID: 20664929
[TBL] [Abstract][Full Text] [Related]
2. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer.
Nakamura K; Hongo A; Kodama J; Hiramatsu Y
Int J Cancer; 2011 Jun; 128(11):2613-24. PubMed ID: 20715109
[TBL] [Abstract][Full Text] [Related]
3. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Ann Oncol; 2009 Jan; 20(1):63-70. PubMed ID: 18689863
[TBL] [Abstract][Full Text] [Related]
7. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Aug; 35(2):239-48. PubMed ID: 19578736
[TBL] [Abstract][Full Text] [Related]
8. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
[TBL] [Abstract][Full Text] [Related]
9. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
11. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells.
Garcia N; Al-Hendy A; Baracat EC; Carvalho KC; Yang Q
Cells; 2020 Dec; 10(1):. PubMed ID: 33396427
[TBL] [Abstract][Full Text] [Related]
13. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.
Edris B; Espinosa I; Mühlenberg T; Mikels A; Lee CH; Steigen SE; Zhu S; Montgomery KD; Lazar AJ; Lev D; Fletcher JA; Beck AH; West RB; Nusse R; van de Rijn M
J Pathol; 2012 Jun; 227(2):223-33. PubMed ID: 22294416
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity.
Szabo R; Hobson JP; List K; Molinolo A; Lin CY; Bugge TH
J Biol Chem; 2008 Oct; 283(43):29495-504. PubMed ID: 18713750
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase.
Larsen BR; Steffensen SD; Nielsen NV; Friis S; Godiksen S; Bornholdt J; Soendergaard C; Nonboe AW; Andersen MN; Poulsen SS; Szabo R; Bugge TH; Lin CY; Skovbjerg H; Jensen JK; Vogel LK
Exp Cell Res; 2013 Apr; 319(6):918-29. PubMed ID: 23333561
[TBL] [Abstract][Full Text] [Related]
16. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line.
Chuang TD; Ho M; Khorram O
Reprod Sci; 2015 May; 22(5):563-71. PubMed ID: 25305131
[TBL] [Abstract][Full Text] [Related]
17. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
18. [Effect of HAI-1 over-expression on in vitro growth and migration/motility of SW620 cells].
Cao J; Ye JJ
Shi Yan Sheng Wu Xue Bao; 2005 Jun; 38(3):183-9. PubMed ID: 16044910
[TBL] [Abstract][Full Text] [Related]
19. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
20. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
